OMERACT Filter Evidence Supporting the Measurement of At-work Productivity Loss as an Outcome Measure in Rheumatology Research

Abstract

Our current recommendations for at-work productivity loss measures are: WALS (Workplace Activity Limitations Scale), WLQ PDmod (Work Limitations Questionnaire with modified physical demands scale), WAI (Work Ability Index), WPS (Arthritis-specific Work Productivity Survey), and WPAI (Work Productivity and Activity Impairment Questionnaire). Our future research focus will shift to confirming core contextual factors to consider in the measurement of worker productivity.

The Quality of Working Life Questionnaire for Cancer Survivors: Sufficient responsiveness for use as a patient-reported outcome measurement

“…When we compared our results with other on-the-job measurement instruments such as the Work Limitation Questionnaire (WLQ) (Tamminga et al, 2014), the Work Role Functioning Questionnaire (WRFQ) (Abma, van der Klink, & Bultmann, 2013), and various atwork productivity measures (Beaton et al, 2016), we found similar or slightly better responsiveness and interpretability scores for the QWLQ-CS. For instance, responsiveness of the WLQ among cancers survivors showed an AUC of 0.68, with an SDC_group of 3.0 and a MIC of 2.9, whereas for the WRFQ an SDC_group of 5.8 (calculated based on their SEM) and an MIC of 9.0 were found (Ramada et al, 2014).…”

“…For instance, responsiveness of the WLQ among cancers survivors showed an AUC of 0.68, with an SDC_group of 3.0 and a MIC of 2.9, whereas for the WRFQ an SDC_group of 5.8 (calculated based on their SEM ) and an MIC of 9.0 were found (Ramada et al, ). Furthermore, Beaton et al reported in their review of two multi‐item at‐work productivity measures that the AUC ranged from 0.62 to 0.84 (Beaton et al, ).…”

Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjögren's Syndrome: A General Population–Based Study

“…Productivity costs/gains are not usually considered by health care payers but are impor tant to patients (35) and workplace stakeholders. Productivity costs/gains are not usually considered by health care payers but are impor tant to patients (35) and workplace stakeholders.…”

“…Clearly, more research is needed to address the consid erable productivity burden of SARDs. Productivity costs/gains are not usually considered by health care payers but are impor tant to patients (35) and workplace stakeholders. The deter minants of productivity costs that we identified among SARDs patients included pain, fatigue, smoking, low education, and being overweight.…”

Work Disability and the Cost-effectiveness of Drugs to Treat Rheumatic Diseases — Time for a New Dialogue?

“…The updated core set of outcome measures to be assessed in PsA RCT now includes work as an outcome (under the umbrella term of Participation) 9 . A variety of measures are used to assess worker productivity in RCT, and 5 have been endorsed by Outcome Measures in Rheumatology Clinical Trials (OMERACT): The Workplace Activity Limitations Scale, the Work Limitations Questionnaire with modified physical demands scale, the Work Ability Index, the Arthritis-specific Work Productivity Survey, and the Work Productivity and Activity Impairment Questionnaire (WPAI) 10 . Efforts are currently under way to evaluate the validity of all outcome See Biologics and work productivity, page 1124 measures used for the assessment of PsA against the OMERACT filter, to derive a "core set" of measurement instruments for use in trials.…”